Insulet Corporation income statement

In fiscal 2025, Insulet Corporation reported revenue of $2.71bn, up 30.7% on the year before, operating income of $474m (a 17.5% margin) and net income of $247m, or $3.48 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Insulet Corporation: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	66	97	152	211	247	231	264	367	464	564	738	904	1,099	1,305	1,697	2,072	2,708	3,054
Cost of revenue	48	53	86	119	135	104	131	156	187	194	258	322	347	500	537	626	768	883
Gross profit	18	44	67	92	112	127	133	211	277	370	480	582	752	806	1,160	1,446	1,940	2,170
Research and development	13	17	22	24	22	28	43	56	76	95	132	147	160	180	205	220	301	346
Selling, general and administrative	—	—	—	—	—	—	—	—	—	248	298	384	466	588	735	917	1,165	1,309
Selling and marketing	38	35	43	53	56	51	78	94	124	—	—	—	—	—	—	—	—	—
General and administrative	27	27	44	51	64	58	60	72	85	—	—	—	—	—	—	—	—	—
Operating income	−59	−39	−42	−36	−29	−9	−49	−11	−7	27	50	52	126	38	220	309	474	516
Interest expense	—	—	—	16	17	15	13	14	21	29	35	48	62	36	36	43	59	59
Net interest income	—	—	—	—	—	—	—	—	—	−21	−28	−45	−61	−27	—	—	—	—
Income before tax	−72	−61	−57	−52	−45	−48	−61	−27	−27	5	15	10	21	10	215	300	340	495
Income tax	—	—	−11	0	0	0	0	0	0	2	3	3	4	5	8	−118	92	119
Net income	−72	−61	−46	−52	−45	−52	−74	−29	−27	3	12	7	17	5	206	418	247	375
Diluted EPS	−$2.43	−$1.54	−$0.98	−$1.08	−$0.83	−$0.93	−$1.29	−$0.48	−$0.46	$0.05	$0.19	$0.10	$0.24	$0.07	$2.94	$5.78	$3.48	$5.32
Diluted shares (average)	—	40m	47m	48m	54m	56m	57m	57m	58m	61m	62m	66m	69m	70m	74m	74m	72m	71m
EBITDA	−54	−34	−34	−25	−17	3	−33	3	7	43	78	107	183	101	293	390	564	615

US$ millions unless shown otherwise. Fiscal quarters.

Insulet Corporation: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	544	598	569	649	706	784	762	802
Cost of revenue	167	167	160	197	196	215	233	239
Gross profit	377	431	409	452	510	569	529	563
Research and development	55	61	60	73	77	91	90	88
Selling, general and administrative	234	261	261	258	315	331	317	345
Operating income	88	109	89	121	118	146	122	130
Interest expense	12	9	9	20	16	15	15	14
Provision for credit losses	—	—	−5	—	—	—	—	—
Income before tax	83	111	48	28	123	140	113	119
Income tax	5	11	13	6	35	39	22	24
Net income	78	101	35	23	88	102	91	95
Diluted EPS	$1.08	$1.38	$0.50	$0.32	$1.24	$1.43	$1.30	$1.37
EBITDA	109	131	111	143	140	171	148	156

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GMED vs PODD PODD vs RVTY PODD vs QDEL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Insulet Corporation's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Insulet Corporation.